SCHEMBL560472

SCHEMBL560472

Nc1ncc(Nc2cccnc2)nc1C(=O)Nc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ATR Q13535 18/20 0.69
CYP3A4 P08684 1/20 0.69
PRKCI P41743 1/20 0.61
PRKDC P78527 5/20 0.60
CCNE2 O96020 1/20 0.54
CCNE1 P24864 1/20 0.54
CDK2 P24941 1/20 0.54
GSK3B P49841 1/20 0.54
ATM Q13315 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560845 0.90 ATR (0.70) ATRCYP3A4PRKDCATM
SCHEMBL560267 0.89 ATR (0.68) ATRCYP3A4PRKCIPRKDCATM
SCHEMBL2484903 0.81 ATR (1.00) ATRCYP3A4PRKDCATM
SCHEMBL559716 0.81 ATR (0.69) ATRCYP3A4PRKDCATM
SCHEMBL6615544 0.81 ATR (0.88) ATRCYP3A4PRKDCCCNE2CCNE1
SCHEMBL411951 0.80 ATR (0.75) ATRCYP3A4PRKCIPRKDCCCNE2
SCHEMBL12518638 0.79 PRKCI (0.69) ATRCYP3A4PRKCIPRKDCCCNE2
SCHEMBL559940 0.77 ATR (0.51) ATRCYP3A4PRKDCATM
SCHEMBL10134810 0.77 RAB9A (0.56) GSK3B
SCHEMBL559881 0.76 ATR (1.00) ATRCYP3A4PRKDCATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
EP-2569289-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2013-03-20 EP disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
WO-2011143419-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed
WO-2011143419-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 ATR 1/4885CYP3A4 4183/4885PRKCI 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.